111 related articles for article (PubMed ID: 27716843)
1. Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice.
Costarelli S; Cozzi-Lepri A; Lapadula G; Bonora S; Madeddu G; Maggiolo F; Antinori A; Galli M; Di Perri G; Viale P; d'Arminio Monforte A; Gori A;
PLoS One; 2016; 11(10):e0160761. PubMed ID: 27716843
[TBL] [Abstract][Full Text] [Related]
2. Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice.
Costarelli S; Cozzi-Lepri A; Lapadula G; Bonora S; Madeddu G; Maggiolo F; Antinori A; Gori A; D'Arminio-Monforte A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19571. PubMed ID: 25394078
[TBL] [Abstract][Full Text] [Related]
3. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR;
J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984
[TBL] [Abstract][Full Text] [Related]
4. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
Goicoechea M; Liu S; Best B; Sun S; Jain S; Kemper C; Witt M; Diamond C; Haubrich R; Louie S;
J Infect Dis; 2008 Jan; 197(1):102-8. PubMed ID: 18171292
[TBL] [Abstract][Full Text] [Related]
5. Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.
Pontrelli G; Cotugno N; Amodio D; Zangari P; Tchidjou HK; Baldassari S; Palma P; Bernardi S
BMC Infect Dis; 2012 Jan; 12():18. PubMed ID: 22269183
[TBL] [Abstract][Full Text] [Related]
6. Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation.
Yoshino M; Yagura H; Kushida H; Yonemoto H; Bando H; Ogawa Y; Yajima K; Kasai D; Taniguchi T; Watanabe D; Nishida Y; Kuwahara T; Uehira T; Shirasaka T
J Infect Chemother; 2012 Apr; 18(2):169-74. PubMed ID: 21968965
[TBL] [Abstract][Full Text] [Related]
7. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
8. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.
Huang F; Scholl P; Huang DB; MacGregor TR; Taub ME; Vinisko R; Castles MA; Robinson P
Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):163-70. PubMed ID: 20977679
[TBL] [Abstract][Full Text] [Related]
9. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M
HIV Clin Trials; 2013; 14(3):81-91. PubMed ID: 23835510
[TBL] [Abstract][Full Text] [Related]
10. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.
Blanco JR; Caro-Murillo AM; Castaño MA; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Riera M; Pulido F; Vera F; Romero-Palacios A; Aguirrebengoa K; Portilla J; Ferrer P; Pedrol E
HIV Clin Trials; 2013; 14(5):204-15. PubMed ID: 24144897
[TBL] [Abstract][Full Text] [Related]
11. Renal function with use of a tenofovir-containing initial antiretroviral regimen.
Gallant JE; Moore RD
AIDS; 2009 Sep; 23(15):1971-5. PubMed ID: 19696652
[TBL] [Abstract][Full Text] [Related]
12. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
[TBL] [Abstract][Full Text] [Related]
13. Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies.
Winston J; Chonchol M; Gallant J; Durr J; Canada RB; Liu H; Martin P; Patel K; Hindman J; Piontkowsky D
HIV Clin Trials; 2014; 15(6):231-45. PubMed ID: 25433663
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
[TBL] [Abstract][Full Text] [Related]
15. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States.
Juday T; Grimm K; Zoe-Powers A; Willig J; Kim E
AIDS Care; 2011 Sep; 23(9):1154-62. PubMed ID: 21500025
[TBL] [Abstract][Full Text] [Related]
17. Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
Brunetta J; Moreno Guillén S; Antinori A; Yeni P; Wade B; Johnson M; Shalit P; Ebrahimi R; Johnson B; Walker I; De-Oertel S
Patient; 2015 Jun; 8(3):257-67. PubMed ID: 25808940
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad
Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Uy J; Yang R; Wirtz V; Sheppard L; Farajallah A; McGrath D
AIDS Care; 2011 Nov; 23(11):1500-4. PubMed ID: 21732894
[TBL] [Abstract][Full Text] [Related]
20. Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments.
Achhra AC; Nugent M; Mocroft A; Ryom L; Wyatt CM
Curr HIV/AIDS Rep; 2016 Jun; 13(3):149-57. PubMed ID: 27130284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
